Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Operating Income of -$7.80 million for fiscal year 2025.
ADIAL PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.80M | +5.9% |
| 2024 | -$8.28M | -20.3% |
| 2023 | -$6.89M | +36.6% |
| 2022 | -$10.86M | +43.7% |
| 2021 | -$19.29M | -76.5% |
| 2020 | -$10.93M | -32.5% |
| 2019 | -$8.24M | -18.0% |
| 2018 | -$6.99M | -602.0% |
| 2017 | -$995.3K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.76M | +20.2% | +6.3% |
| June 30, 2025 | -$1.88M | +17.7% | +17.0% |
| March 31, 2025 | -$2.27M | -22.9% | -2.5% |
| September 30, 2024 | -$2.21M | -62.9% | +3.3% |
| June 30, 2024 | -$2.29M | -54.8% | -24.0% |
| March 31, 2024 | -$1.85M | +18.7% | -35.9% |
| September 30, 2023 | -$1.36M | +46.8% | +8.1% |
| June 30, 2023 | -$1.48M | +54.5% | +34.9% |
- ADIAL PHARMACEUTICALS, INC. showed an increase of +5.9% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, ADIAL PHARMACEUTICALS, INC.’s operating income has declined by 683.6% (from -$995.3 thousand to -$7.80 million).
- The most recent figure is from ADIAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: